News

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

Jan 8, 2021

IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

IDL Biotech announced it has signed an agreement with Beckman Coulter for licensing IDL’s entire range of manual ELISA tumor markers. The licensing agreement provides Beckman Coulter with global sales rights and enables IDL to sell material for production and to receive royalties. The agreement has been formally countersigned by Immunotech, a Beckman Coulter subsidiary.

The tumor markers included in the ELISA platform are TPS®, TPAcyk™, MonoTotal® and UBC®.

Read the full press release here (Swedish)

Strategy update: IDL Diagnostics

Nov 28, 2025 | , ,

A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...

read more

Thesis projects at IDL Diagnostics.

Jun 10, 2025 | ,

We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...

read more